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Background: To tackle the missing heritability of sporadic heart failure, we screened for novel 
heart failure-associated genetic variants in the Finnish population and functionally 
characterized a novel variant in vitro and in vivo. 
Methods and results: Heart failure-associated variants were screened in genotyping 
array data of the FINRISK study, consisting of 994 cases and 20,118 controls. Based on logistic 
regression analysis, a potentially damaging variant in TRIM55 (rs138811034), encoding an 
E140K variant, was selected for validations. In HL-1 cardiomyocytes, we used CRISPR/Cas9 
technology to introduce the variant in the endogenous locus, and additionally TRIM55 wildtype 
or E140K was overexpressed from plasmid. Functional responses were profiled using whole-
genome RNA sequencing, RT-PCR and Western analyses, cell viability and cell cycle assays 
and cell surface area measurements. In zebrafish embryos, cardiac contractility was measured 
using videomicroscopy after CRISPR-mediated knockout of trim55a or plasmid 
overexpression of TRIM55 WT or E140K. Genes related to muscle contraction and cardiac 
stress were highly regulated in Trim55 E140K/- cardiomyocytes. When compared to the 
WT/WT cells, the variant cells demonstrated reduced viability, significant hypertrophic 
response to isoproterenol, p21 protein overexpression and impaired cell cycle progression. In 
zebrafish embryos, the deletion of trim55a or overexpression of TRIM55 E140K reduced 
cardiac contractility as compared to embryos with wildtype genotype or overexpression of WT 
TRIM55, respectively. 
Conclusions: A previously uncharacterized TRIM55 E140K variant demonstrated a 
number of functional implications for cardiomyocyte functions in vitro and in vivo. These 
findings suggest a novel role for TRIM55 polymorphism in predisposing to heart failure. 
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1. Introduction 
Heart failure is a lethal cardiac disorder with various causes. The overall prevalence of heart 
failure is 1-2% in a general population [1], while the lifetime risk for people at age of 55 has 
been estimated to be 33% for men and 29% for women [2]. Genetic background of heart failure 
risk is only partly understood. In total, approximately 18% of heart failure risk is explained by 
heritable factors [3]. However, no common genes or signaling pathways accounting for 
majority of the heritability of heart failure are currently known [4]. Functional characterization 
of novel heart failure-associated genetic variants would therefore help in identifying key 
proteins and pathways underlying the pathogenesis. Population-specific genetic risk factors 
enable genetic screenings and more thorough clinical follow-up as well as early treatment of 
the high-risk individuals. Genetic findings may also lead to the discovery of novel therapeutic 
targets for heart failure. 
 Several genetic variants causing familial cardiomyopathies and related heart failure are 
well characterized. A large proportion, up to 50%, of the hypertrophic cardiomyopathy 
syndromes are caused by mutations in MYBPC3 and MYH7 genes [5]. For dilated 
cardiomyopathy, the genetic background is well-defined in approximately 30-35% of the cases 
where TTN, LMNA, MYH7 and TNNT2 account for the majority of the cases [5]. For sporadic 
heart failure, the landscape of contributing genes is wider and the results of individual variants 
are often controversial [6]. For instance, variants in genes related to renin-angiotensin-
aldosterone system (ACE, AT1R, AGT), sympathetic nervous system (ADRB1, ADRB2, 
ADRA2C), inflammatory system (e.g. CTLA4, IL4) and drug metabolism (CYP2D6) have been 
identified as modifiers of susceptibility, therapeutic response and prognosis of heart failure [6]. 
TRIM55 gene encodes a protein known as TRIM55 or MURF2, which is highly 
expressed in the heart and skeletal muscle. TRIM55 contains a RING zinc finger domain and it 
has been shown to be involved in muscle sarcomere assembly and to function as a ubiquitin E3 
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ligase [7]. Loss of its function, together with Trim63, causes heart failure and cardiac 
hypertrophy in newborn mice, their functions being thus necessary but redundant [8]. In another 
study on a knockout mouse model, loss of both Trim55 and Trim63 caused severe cardiac 
hypertrophy, while the loss of each gene alone caused only mild, statistically non-significant 
increase in heart weight [9]. In a model of experimental hypertrophy using transaortic 
constriction, hypertrophic response was significantly more pronounced in mice lacking Trim63, 
while mice lacking Trim55 did not demonstrate any difference to wildtype controls [10]. 
However, in a mouse model of diabetic cardiomyopathy, Trim55 knockout mice developed 
more severe hypertrophy and early onset systolic dysfunction [11]. Additionally, in a rat model 
of spontaneous cardiac hypertrophy, Trim55 expression was negatively correlated with left 
ventricular mass, and in human samples, TRIM55 expression was lower in idiopathic dilated 
cardiomyopathy, as compared to healthy heart [12]. TRIM55 is thus implicated in heart failure 
pathogenesis but the effects of any deleterious genetic variants have not been characterized in 
detail earlier. 
Here, we carried out a genetic screening for novel variants associated with heart failure 
using genotyping array and outcome data from a large, Finnish population-based FINRISK 
survey study [13]. Based on the genetic screening results, a potentially damaging exonic variant 
in TRIM55, encoding E140K variant in the protein, was selected for further validation in vitro 
and in vivo. The variant was shown to affect cardiomyocyte-specific functions in 
CRISPR/Cas9-modified HL-1 cardiomyocytes and contractility of the zebrafish heart. These 
findings suggest a novel role for a previously uncharacterized TRIM55 E140K variant, where 
the effect of the variant may be even dominantly negative on heart failure pathogenesis. 
 
 
2. Materials and Methods 
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Detailed methods are available in the data supplement. Briefly, CRISPR/Cas9 technology was 
used to introduce the TRIM55 E140K variant, identified in GWAS analysis for heart failure in 
the FINRISK data, in the endogenous locus in HL-1 cardiomyocytes. Additionally, plasmid 
overexpression of TRIM55 wildtype and E140K variant was used in functional analyses. 
Transcriptional and protein-level responses were profiled using whole-genome RNA 
sequencing, RT-PCR and Western analyses, respectively. Cellular responses were measured 
using cell viability and cell cycle assays, immunofluorescence microscopy and cell surface area 
measurements. In zebrafish embryos, cardiac contractility was measured using 
videomicroscopy after CRISPR-mediated knockout of trim55a or plasmid overexpression of 
TRIM55 WT or E140K. Zebrafish experiments were conducted according to normal procedures 
and regulations under the license no. MMM/465/712-93 (issued by the Finnish Ministry of 
Forestry and Agriculture). The genetic and clinical data from the FINRISK study cohort [13] 
are available from the THL Biobank of the National Institute for Health and Welfare upon 
research application.  
 
3. Results 
3.1 A previously uncharacterized exonic variant in TRIM55 is associated with heart failure in 
the Finns 
Heart failure-associated genetic variants were screened for in the Finnish population using the 
genotyping array and outcome data from the FINRISK study. Forty-seven percent (698 
individuals) of the individuals with heart failure in the cohort had coronary artery disease. 
Imputed genotype data passing quality control were available for 20,118 individuals, out of 
which 994 had heart failure. Logistic regression analysis confirmed several loci previously 
associated with heart failure that demonstrated nominal association in the Finnish population 
cohort (P < 0.001), either with heart failure or cardiomyopathies, including ACE [6], ANKRD1, 
 6 
DSG2, MYBPC3 and TTN [5]. There were four genome wide-significant variants (P < 5 x 10-
8), all located in chromosome 16 (Table 1). 
The regions with most highly-associated variants were examined in detail to identify 
candidate causal coding variants in linkage disequilibrium (LD) with the lead variants 
(LocusZoom plots of selected regions are shown in Supplemental Figure S1).  To make the 
functional validations feasible in the cardiomyocytes, we narrowed our analyses to exonic, 
coding variants only. Of the most significantly heart failure-associated variants (Table 1), the 
lead single nucleotide polymorphism (SNP) rs143488191 in chromosome 16 in intergenic 
region between RRN3P2 and SNX29P2 did not have any common coding variants in high LD. 
A coding variant in SPN gene, rs2229654, was strongly associated with heart failure, but SPN 
is mostly expressed in leukocytes, making it less attractive for functional validations. Similarly, 
the variant in chromosome 12, rs73407741, is intronic and the FAM222A gene is predominantly 
expressed in neural and endocrine tissues.  
The lead variant in the chromosome 8, rs117667921, is located in an intron of ADHFE1, 
which encodes the iron containing alcohol dehydrogenase 1 (Fig. 1A). An exonic variant 
rs138811034 in TRIM55 gene was found to be in complete LD with the lead SNP (D’ = 1). 
Rs138811034 did not demonstrate an independent association with heart failure in our study 
cohort (OR 1.522, P = 0.377) (Table 2), probably due to lack of resolution in the genotyping 
array. Minor allele frequency for the variant in the Finnish population is 0.16%, and in other, 
non-Finnish European populations it is 0.23%, based on the gnomAD database [14]. The variant 
encodes a missense E140K variant in the TRIM55 protein that is potentially damaging as 
predicted with the Ensembl Variant Effect Predictor [15]. TRIM55 has previously been shown 
to have implications on development of the heart in mouse models [7]. Additionally, loss of 
TRIM55 is associated with hypertrophy and heart failure in mouse and rat models [11,12] and 
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in human [12,16]. However, the E140K variant has not been studied earlier in detail, and it was 
therefore selected for further functional validation. 
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allele OR P-value Gene 
16 
chr16:2913470
0 A 3.776 4.07 x 10-9   
16 
chr16:2925738
1 A 3.280 1.87 x 10-8   
16 rs143488191 T 3.333 2.09 x 10-8   
16 rs148456921 A 3.311 4.08 x 10-8   
16 
chr16:2937109
9 A 3.282 5.07 x 10-8   
16 rs199707538 G 3.255 6.05 x 10-8   
16 rs2229654 G 3.274 8.65 x 10-8 SPN 
12 rs73407741 T 0.5688 1.64 x 10-7 FAM222A 
8 rs117667921 A 2.366 2.45 x 10-7 ADHFE1 
4 rs77080662 T 2.400 2.64 x 10-7   
 
OR, odds ratio 
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Table 2. The lead variant in chromosome 8 and two variants in high LD with the lead variant. 
Chromosome rsID 
Alternative 
allele OR P-value Gene MAF 
8 rs117667921 A 2.366 2.45 x 10-7 ADHFE1 0.017 
8 rs138811034 A 1.522 0.377 TRIM55 0.0016 
8 rs112144279 A 2.124 4.46 x 10-6 DNAJC5B 0.017 
 




3.2 3D model for TRIM55 reveals a surface exposed location for the E140K variant 
To predict the position and putative consequences caused by the E140K variation on the 3D 
structure and molecular interactions of TRIM55, dimeric 3D models for the TRIM55 B2 
domain were constructed by homology modeling based on the X-ray structure of TRIM63. 
Despite the slightly higher sequence identity between TRIM54 and TRIM55, TRIM63 structure 
was selected as a template (Supplemental Figure S2A) since its two different dimeric forms 
have been evaluated in detail by Mrosek et al. [17]. Based on their analysis, the dimeric form 
in the asymmetric unit of the crystal, which corresponds to the dimer of TRIM55 B2 (dimer 1 
in Supplemental Figure S2B), is consistent with the known composition of the dimeric TRIM 
fold. In dimer 1, E140s are located on the surface of the protein, whereas in the other TRIM55 
B2 dimer (dimer 2) resulting from the crystallographic symmetry of TRIM63, the E140 residues 
contribute to the dimer interface (Supplemental Figure S2C). 
The surface presentation of E140K variant clearly demonstrates the effect of replacing 
a negatively charged E140 with a positively charged lysine in the dimer interface. In the 
TRIM55 B2 dimer 2 (Fig. 1B), one of the E140s is involved in an extensive network of ionic 
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interactions and both of E140s interact with H164. In the E140K variant, these favorable 
interactions are lost (Fig. 1C). Interestingly, the analysis of the TRIM63 oligomeric structure 
revealed that in the presence of the B2 domain it formed higher-order oligomeric species but in 
the absence of B2 the protein was dimeric [17]. Thus, the dimer 2 interface where E140 resides 
is plausibly involved in forming higher-order oligomers of TRIM55. The structural comparison 
of the TRIM55 B2 model with the heterodimer of the RING domains of BRCA1 and BARD1 
(PDB ID 1JM7) [18] (Supplemental Figure S2D) shows that E140 in the TRIM55 B2 monomer 
corresponds to the acidic D40 in BRCA1 facing towards the heterodimer interface in the 
BRCA1 - BARD1 complex. Similarly, E140 in the dimer 2 interface is likely to be involved in 
forming the heterodimeric complexes of TRIM55. As a conclusion, our results suggest that the 
formation of both higher-order oligomers and heterodimeric complexes might be disturbed in 
the TRIM55 E140K variant. 
 
3.3 Loss of functional Trim55 in HL-1 cardiomyocytes alters gene expression regulation of 
contractility and cardiac stress 
To study the functional effects of TRIM55 E140K variant, located in exon 3, in vitro, stable 
cardiomyocyte lines carrying Trim55 variants were generated with CRISPR/Cas9 using mouse 
HL-1 cells as background. Out of 49 CRISPR-treated single-cell clones subjected to screening, 
two carried the E140K coding variant in their genome, both together with a deletion allele 
(E140K/- genotype) (Fig. 2A). One of these lines was randomly chosen for validations. No cell 
lines carrying homozygous E140K/E140K or heterozygous WT/E140K genotypes were 
identified among the generated clones. For comparison of the phenotype of the E140K/- line, 
predicted to be functionally a double-knockout, cell lines carrying heterozygote (WT/-) and 
homozygote (-/-) knockout genotypes were included in the analyses (Fig. 2A). The deletion 
alleles in all three variant lines caused a nonsense mutation, leading to a premature stop codon. 
 11 
Lengths of protein products of deletion alleles were 158 amino acids in E140K/- line, 146 and 
159 amino acids in -/- line and 146 amino acids in WT/- line.  
 Protein and mRNA expression levels in the cell lines were assessed with Western 
blotting and quantitative RT-PCR, respectively. In E140K/- line, the TRIM55 protein level was 
reduced approximately to 70% of the wildtype, the difference being borderline significant (P = 
0.057; n = 4) (Fig. 2B). In -/- line, the protein expression was completely abolished, while in 
WT/- cells the expression was approximately 50% of the WT/WT line (P = 0.043; n = 4) (Fig. 
2B). Similarly, Trim55 mRNA expression was markedly reduced in -/- and WT/- lines, 
compared to WT/WT, even though the corrected P-values did not reach statistical significance 
level (Fig. 2C). In E140K/- cells, the mRNA expression level remained relatively unchanged 
as compared to WT/WT line (Fig. 2C). Binding sites of primers used in the RT-PCR analysis 
in exons 3 and 4 are shown in Supplemental Figure S3. 
For systematic characterization of transcriptomic alterations caused by Trim55 variants, 
the cell lines were subjected to whole-genome RNA sequencing to identify differentially 
expressed genes and signaling pathways implicated in heart failure. We performed 
unsupervised hierarchical clustering of the variant cell lines based on 82 most highly-regulated 
genes in the variant cell lines (selected based on their expression differences in the smallest 5% 
percentile of adjusted P-values, with a cut-off of P < 7.06 x 10-13, as compared to WT/WT 
cells), which grouped E140K/- and -/- lines together, and closer to WT/WT line, while WT/- 
samples formed their own cluster (Fig. 3A). No batch effects were observed between replicates 
within each cell line (Supplemental Figure S4). 
Gene set enrichment analysis using gene ontology (GO) terms for differentially 
expressed genes in E140K/- line demonstrated enriched regulation of pathways related to 
muscle contraction, contractile structures, and heart and muscle development (adjusted P = 
0.021; Fig. 3B), which are in line with the known functions of Trim55. When focusing on the 
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top-10 leading edge genes of the most regulated pathway in E140K/- cells 
(GO_REGULATION_OF_MUSCLE_CONTRACTION), the E140K/- and -/- samples 
clustered again together, underlining the deleterious effect of E140K as compared to WT/WT 
and WT/- samples, especially in Nppa, Myl7 and Adra2b genes (Fig. 3C and 3D). These three 
top leading edge genes of the pathway were selected for validation by quantitative RT-PCR. 
In the independent validation samples, expression level of Nppa was consistently higher 
in E140K/- cells (P = 0.101; n = 3), as compared to WT/WT samples, whereas Nppa expression 
was lower in WT/- samples (P = 0.101; n = 3) (Fig. 3D). Atrial natriuretic peptide encoded by 
Nppa is an established marker for cardiac stress and heart failure [19]. Myl7 expression was 
also consistently lower in the E140K/- line (P = 0.061; n = 3), similarly to Adra2b (P = 0.150; 
n = 3) (Fig. 3D). We note that all the reported P-values are FDR-corrected, which together with 
small sample numbers explain the moderate significance levels. However, in the E140K/- line, 
the direction of regulation of all the validated genes were in concordance with the RNA 
sequencing results. These results indicate that the loss of functional Trim55 regulates genes 
related to cardiac contractility and stress. 
 
3.4 Trim55 E140K variant reduces cardiomyocyte viability and cell cycle progression and 
predisposes to hypertrophy 
To investigate the phenotypic alterations in HL-1 cells carrying the defective Trim55 variants, 
we measured functional readouts quantifying cellular viability, cell cycle progression and 
hypertrophy. It was observed that the viability of the cells was significantly reduced in the 
E140K/- cells as compared to the WT/WT cells (P = 0.006, n = 4) (Fig. 4A), as well as to WT/- 
cells (P = 0.014, n = 4), suggesting a damaging role of E140K variant. 
To further evaluate the potential reason for the observed difference in the overall 
measure of viability or cell number, p21 expression as a marker for cell cycle progression was 
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assessed using Western analysis. In E140K/- cells, the p21 expression level was moderately 
higher as compared to WT/WT cells (P = 0.093; n = 5) (Fig. 4B). In RNA sequencing data, no 
differences in expression level of CDKN1A, which encodes p21, were detected in the variant 
cell lines, as compared to WT/WT (E140K/- vs WT/WT: fold change = 1.47, P = 0.572; -/- vs 
WT/WT: fold change = 1.17, P = 0.999; fold change = 1.21, P = 0.793). In flow cytometry-
based cell cycle analysis using propidium iodide for DNA staining, E140K/- cells had 
significantly fewer cells in mitotic G2/M phase as compared to WT/WT cells (P = 0.015; n = 
4) (Fig. 4C). As for WT/- cells, there were fewer cells in S phase as compared WT/WT cells (P 
= 0.004; n = 4), and accumulation of cells was observed in G2/M phase (P = 0.015, n = 4) (Fig. 
4C), indicating either a more rapid progression of cell cycle or alternatively a stop of cell cycle 
progression at checkpoints other than for E140K/- cells. Although the viability of WT/- cells 
was not significantly higher as compared to WT/WT cells (Fig. 4A), the cells were observed to 
grow and become confluent faster than WT/WT cells in cell culture. Therefore, a cessation in 
cell cycle progression seems less likely. 
For measuring the hypertrophic response, the cells were exposed to 48-hour treatment 
with 100 μM isoproterenol. In immunofluorescence analysis of the cell surface area with 
myosin heavy chain staining, each E140K/-, -/- and WT/- cell line demonstrated a significant 
increase in their normalized surface areas (P = 0.001, P < 0.001 and P = 0.018, respectively; n 
= 282-484 individual cells per each group), when challenged with isoproterenol, as compared 
to non-treated controls (Fig. 4D-E). In contrast, WT/WT cells did not show a hypertrophic 
response to isoproterenol treatment. For comparability, the data are normalized within each cell 
line separately (i.e., the median of non-treated controls is set to one), since the average cell sizes 
differed markedly between the cell lines (Supplemental Figure S5). 
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3.5 Trim55 E140K variant affects p62 and SRF protein levels, α-actinin expression and calcium 
transients in cardiomyocytes 
To study the effects of Trim55 variants on its E3 ubiquitin ligase activity, expression 
levels of the known Trim55 interaction partners or ubiquitination targets SRF [9,20], p62 [21] 
and cardiac troponin I (cTnI) [22] were studied in the cell lines. P62 and SRF expression levels 
were lower in E140K/- cells compared to wildtype cells (P = 0.004 and P = 0.034, respectively, 
n = 3), and modestly lower in -/- cells compared to wildtype cells (P = 0.061 and P = 0.072, 
respectively, n = 3), while no changes were detected in cTnI expression (Supplemental Figure 
S6A-C). P62 expression was additionally lower in WT/- cells (P = 0.002). Ubiquitination of 
SRF or p62 was not detected after immunoprecipitation with protein-specific antibodies, 
followed by blotting with anti-poly- and mono-ubiquitin antibodies (Supplemental Figure S6D-
E). Additionally, no changes were detected in total ubiquitination levels between the cell lines 
(Supplemental Figure S6F), which was expectable since TRIM55 is only one of multiple E3 
ligases. Interestingly, lower expression levels of both p62 and SRF were detected in Trim55 
deficient cell lines although it may have been more expected to see their upregulation, assuming 
they are ubiquitination targets of TRIM55. This suggests a complex network of factors 
regulating the activity of these proteins. 
To examine sarcomere structures in the variant cell lines, α-actinin stainings followed 
by immunofluorescence and confocal imaging were used. It was observed that α-actinin 
expression and organization was heterogeneous among cells within the cell lines. However, on 
average E140K/- cells, compared to WT/WT cells, demonstrated a higher staining intensity of 
α-actinin filaments (P < 0.001), which was analyzed using an automated algorithm to identify 
the myofibrillar structures (Supplemental Figure S7A-B). This reflects on the one hand higher 
expression of α-actinin in E140K/- cells (also observed in RNA-seq data, ACTN2 expression 
fold-change = 3.89 compared to WT/WT cells, P = 0.001), and on the other hand aggregated 
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spots of α-actinin in these cells (Supplemental Figure S7A), which may indicate disorganization 
of myofibrils. In -/- and WT/- cells, the α-actinin filament staining was less intensive compared 
to WT/WT cells (P < 0.001 for both comparisons, Supplemental Figure S7A-B). Width-to-
length ratio of filaments was also examined to reveal potential changes in filament morphology. 
While lengths and widths of filaments were greater in E140K/- cells and smaller in -/- and WT/- 
cells, compared to WT/WT cells (data not shown), the width-to-length ratios were virtually 
similar (median = 0.377 for WT/WT, 0.386 for E140K/-, 0.381 for -/- and 0.387 for WT/- cells), 
where the differences were statistically significant only for E140K/- (P = 0.040) and WT/- (P 
= 0.007), compared to WT/WT cells (Supplemental Figure S7C). TRIM55 E140K variant thus 
affects the expression and organization of α-actinin in sarcomeres. 
Additionally, to study the excitability of the cells, we examined the calcium transients 
of the cells using Fluo-4 AM staining, both spontaneously and under pacing. No statistically 
significant differences in spontaneous frequencies or calcium transient amplitudes and decay 
times were detected (data not shown). The trend in frequencies was that TRIM55-variant cells 
demonstrated higher spontaneous frequencies (on average 0.15 Hz for E140K/-, 0.097 Hz for -
/- and 0.11 Hz for WT/- cells), compared to WT/WT cells (on average 0.085 Hz). 
Representative traces of spontaneous transients are shown in Supplemental Figure S7D. 
However, when paced at the frequency of 0.5 Hz (Supplemental Figure S7E), E140K/- cells 
demonstrated significantly higher amplitude of calcium transients (Supplemental Figure S7F), 
with no differences in decay times (Supplemental Figure S7G). This higher excitability is 
potentially a multifactorial process, involving expression changes in both myofibrillar and 
calcium ion handling proteins. Interestingly, GO_CALCIUM_ION_BINDING pathway was 
one of the most highly-regulated pathways in E140K/- cells in RNA-seq analysis (Fig 2B). In 
pacing with 2 Hz frequency, all of the cell lines were capable to capture the rhythm 
(Supplemental Figure S7H, upper panels), even though they demonstrated also aberrant 
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rhythms (Supplemental Figure S7H, lower panels). Especially E140K/- cells repeatedly 
captured initially the pacing with 2:1 ratio, which was later decreased to 3:1 or less, as shown 
in the example trace (Supplemental Figure S7H, E140K/-, lower panel). 
Taken together, E140K/- cells presented a markedly different phenotype than WT/WT 
or WT/- cells, supporting the damaging role of E140K variant. Interestingly, the numerical 
changes in cell viability and p21 expression were even more pronounced in E140K/- than in -
/- cells, suggesting a possible dominant negative role for E140K variant. Moreover, 
overexpression of TRIM55 E140K in wildtype HL-1 cells reduced the cellular viability, as 
compared to TRIM55 WT-transfected cells (P = 0.026; n = 4) (Supplemental Figure S8A-B). 
However, no differences were observed in cell cycle progression (Supplemental Figure S8C). 
A significant hypertrophic response to isoproterenol was observed in control- and TRIM55 
E140K-transfected cells, while there were no significant differences in TRIM55 WT-
transfected cells (Supplemental Figure S8D-E). TRIM55 WT overexpression could thus protect 
from hypertrophy, in contrast to E140K variant. Furthermore, it is worth noting that cell sizes 
of untreated TRIM55 WT-transfected cells were greater than those of control- and E140K-
transfected cells. These data demonstrate that E140K variant of TRIM55 might have negative 
effects on cardiomyocyte viability even when expressed in cells with wildtype protein. 
 
3.6 Knockout of trim55a or overexpression of human TRIM55 E140K reduces cardiac 
contractility in zebrafish embryos 
To further study the implications of TRIM55 E140K variant on the functionality of the heart in 
vivo, a zebrafish embryo model was used. First, the trim55a gene was knocked out from 
zebrafish embryos using transient CRISPR/Cas9 technique. The 1-4-cell stage embryos were 
injected with CRISPR constructs with a pool of three trim55a sgRNAs one day after 
fertilization and the phenotype was measured at four days after fertilization. A representative 
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sequencing chromatogram from the trim55a locus of an edited embryo harboring aberrant 
sequence after sgRNA binding sites is shown in Fig. 5A. On mRNA level, trim55a expression 
was significantly reduced (on average by 41%) after CRISPR treatment (P < 0.001, n = 5 
batches of eight embryos pooled per treatment) (Supplemental Figure S9A). On protein level, 
a 55-kDa band detected in the Western blot analysis, corresponding to the predicted size of the 
known trim55a transcript, was on average 66% lower in trim55a-knockout embryos. The result 
was modestly significant (P = 0.078, n = 5 batches of eight embryos pooled per treatment), due 
to the high variability in control samples (Supplemental Figure S9B-C).  
Videomicroscopically measured fractional shortening of the heart was significantly 
reduced in trim55a-targeting sgRNA-injected embryos, as compared to control sgRNA-injected 
embryos (median (IQR): 0.14 (0.10) vs. 0.17 (0.650); P = 0.002; n = 23 and 24, respectively) 
(Fig. 5B). There were no differences in the heart rate between any groups and no differences in 
fractional shortening between uninjected and control sgRNA-injected embryos (Fig. 5B). 
Additionally, to address possible off-target effects of trim55a sgRNAs, the three sgRNAs were 
injected also separately in an independent experiment. Reduction in fractional shortening was 
replicated in each sgRNA group (Supplemental Figure S10A). Heart rate was also higher in 
sgRNA #7- and #16-injected embryos compared to control sgRNA group (Supplemental Figure 
S10B). End-diastolic diameter was reduced by approximately 2–5% with trim55a knockdown 
by all sgRNAs, compared to control sgRNA group (Supplemental Figure S10C). 
 To specifically assess the effect of TRIM55 E140K, assuming its potential negative 
dominant role, the protein was expressed in constructs encoding TRIM55 WT and E140K with 
a heart specific cardiac myosin light chain 2 (cmlc2, myl7) promoter. A construct with the same 
backbone encoding GFP was used as the control. Heart-specific expression was confirmed with 
fluorescence microscopy (Fig. 5C). Fractional shortening was significantly lower in the 
embryos injected with either TRIM55 WT and E140K together as in heterozygous state or with 
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TRIM55 E140K construct alone, as compared to TRIM55 WT-injected embryos (median 
(IQR): 0.12 (0.033) for WT/E140K (n = 20) and 0.12 (0.045) for E140K alone (n = 16) vs. 0.16 
(0.02) for WT alone (n = 25); P = 0.004 for both WT/E140K vs. WT and E140K vs. WT) (Fig. 
5D). There were no observed differences in fractional shortening between control- and TRIM55 
WT-injected embryos (P = 0.236; n = 27 and 25, respectively), neither between control-injected 
embryos and uninjected controls (P = 0.142, n = 27 and 18, respectively).  
 We observed no significant difference in heart rate between control-, TRIM55 WT- and 
WT/E140K-injected embryos, whereas heart rate was significantly increased by TRIM55 
E140K injections, as compared to control-injected embryos (median (IQR): 118.5 (11.6) vs. 
106.7 (7.5); P = 0.007; n = 16 and 27, respectively) or WT-injected ones (median (IQR): 118.5 
(11.6) vs. 107.4 (9.5); P = 0.007; n = 16 and 25, respectively). 
Finally, end-diastolic diameter (EDD) and end-systolic diameter (ESD) in CRISPR 
knockout experiment and TRIM55 overexpression experiment shown in Figure 5 were 
analyzed to address changes in the sizes of the ventricles. Trim55a CRISPR knockout slightly 
reduced EDD compared to uninjected and control-injected embryos while no differences in 
ESD were observed (Supplemental Figure S11A-B), similarly to the experiment with separate 
sgRNA injections (Supplemental Figure S10C). Trim55a knockout did not thus cause a dilated 
phenotype. TRIM55 overexpression did not affect ventricular size (Supplemental Figure S11C-
D).  
These data indicate that the overexpression of TRIM55 E140K, but not TRIM55 WT, 
affects the functionality of the heart. This further supports the damaging and dominant-negative 





To improve our understanding of the genetic background of heart failure risk, we screened for 
novel heart failure-associated genetic variants in the Finnish population and selected a missense 
variant in TRIM55 for functional validations in vitro and in vivo. This variant, rs138811034, 
encoding E140K variant in the protein, was shown to be functionally deficient, demonstrating 
even dominantly negative effects. Although TRIM55 has earlier been shown to have 
implications on heart failure [7,11,12], the details of cellular level perturbations caused by any 
TRIM55 variant have not been characterized earlier. We therefore carried out a systematic 
functional analysis of the E140K variant using CRISPR/Cas9 gene editing in mouse 
cardiomyocytes and zebrafish embryos. 
 In our screening for heart failure-associated variants, moderately significant 
associations for variants in the known heart failure loci were observed, including ACE [6], 
ANKRD1, DSG2, MYBPC3 and TTN [5]. We note that the variants identified in our statistical 
analysis were not the heart failure-associated functional variants identified in these genes in the 
previous studies. This is potentially due to lack of power, resolution of the genotyping array or 
population-specific factors. However, we did not study the possible linkage between the known 
variants and the ones identified in our analysis. The lead SNP in chromosome 8 was located in 
the ADHFE1 gene that is involved in adipogenesis [23], and it has also been shown to have 
oncogenic functions [24]. In the search for variants in high LD with this lead SNP, we initially 
identified an intronic variant in DNAJC5B (rs112144279, r2 = 0.64) (Table 2). Interestingly, 
another variant in DNAJC5B has been shown to be associated with the effectiveness of 
pravastatin therapy to prevent coronary artery disease events [25]. The DNAJC5B variant was, 
however, omitted from the functional analyses due to residing in an intron.  
The rs138811034 variant in TRIM55 that was chosen for functional validations is the 
third most frequent missense variant of TRIM55 in the ExAC database [14,26]. Rare 
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nonsynonymous (i.e. missense, insertion or deletion) variants in TRIM55, and also in TRIM63, 
have been shown to contribute to more severe phenotype of human hypertrophic 
cardiomyopathy [16]. The patients with pathogenic variants in these genes were younger and 
had greater left ventricular wall thickness than patients without these variants [16]. However, 
the E140K variant was not identified in this cohort. 
In our results on HL-1 cardiomyocytes, CRISPR-mediated knockout of Trim55 was 
sufficient to cause a significant hypertrophic response to isoproterenol and it also affected the 
cell cycle progression. However, cell cycle was not among the significantly regulated pathways 
in the GSEA analysis, and for instance, no alterations in CDKN1A expression were detected in 
RNA sequencing. This indicates that TRIM55 deletion potentially affects the cell cycle at post-
transcriptional or post-translational level. In RNA-seq validation results, Nppa mRNA 
expression level was higher in E140K/- and -/- cells while it was lower in WT/- cells compared 
to WT/WT cells. It is likely that the observed difference is affected by the SRF-regulated Nppa 
expression, as we observed in Western blot analyses the relative upregulation of a shorter, 
possibly inhibitory isoform of SRF studied by Davis et al. [27] in WT/- cells (Supplemental 
Figure S6A-D). Moreover, it has been shown that complete SRF knockout in mice causes 
cardiomyopathy and increases Nppa expression [28,29]. We further confirmed the role of 
Trim55 in cardiomyocyte phenotype with siRNA-mediated knockdown of Trim55 expression 
in WT HL-1 cells, which reduced the cellular viability (Supplemental Figure S12A-B), and 
hence provides complementary support for the phenotypic effect. In zebrafish embryos, the 
knockout of trim55a alone was sufficient to decrease cardiac contractility in vivo. Our results, 
combined with the previous studies, therefore suggests that functionality of TRIM55 modulates 
the susceptibility to and the phenotype of heart failure, but many of its variants, including 
E140K, have so far remained uncharacterized. 
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In our functional experiments, Trim55 E140K/- cells were significantly less viable than 
WT/WT and WT/- cells and numerically less viable than -/- cells. On the other hand, 
overexpression of human TRIM55 E140K reduced the viability of cardiomyocytes as compared 
to TRIM55 WT overexpression. Cardiomyocytes transfected with TRIM55 E140K 
demonstrated a significant hypertrophic response to isoproterenol while TRIM55 WT-
transfected cells did not. Similarly in zebrafish embryos, overexpression of human TRIM55 
E140K, both alone and together with TRIM55 WT, impaired cardiac contractility while 
TRIM55 WT alone did not. At the same time, heart rate was increased by TRIM55 E140K 
overexpression, as compared to TRIM55 WT. Additionally, differences in heart rate were 
observed in trim55a CRISPR experiments between control injected and sgRNA#7- and #16-
injected embryos. These changes reflect potentially compensatory responses to maintain 
cardiac output. Heart dimensions were not larger in embryos with trim55a knockout or TRIM55 
E140K overexpression, likely due to robust functional reserve. Finally, it is worth noting, that 
in E140K/- cells the calcium transient amplitude was higher, compared to WT/WT cells. This 
suggests that the observed lower contractility in the zebrafish carrying TRIM55 variants is not 
due to impaired calcium cycling. Taken together, E140K seems to have effects on cardiac 
functions even when expressed together with endogenous TRIM55 WT, which suggests a 
dominant negative role. 
 One possible mechanistic explanation for the negative impact is that expressed 
TRIM55 E140K could impact the subcellular localization of the transcription factor serum 
response factor (SRF) in different manner than the wildtype protein. TRIM55 has been shown 
to reduce the amount of SRF in the nucleus [20]. In our GSEA results for motif gene sets, which 
consist of gene sets with genes grouped according to their transcriptional regulatory elements, 
multiple SRF-related gene sets were among the most significantly regulated ones in E140K/- 
cells, as well as in -/- and WT/- cells (Supplemental Table 1). Thus, the SRF-related signaling 
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alterations are not unique to E140K cells only. However, our results suggest that the effect of 
E140K is potentially more harmful than that of simple deletion of the gene. If it indeed is a 
negative dominant variant, E140K could be detrimental even in its heterozygous form. This 
should be further assessed in heterozygous WT/E140K models preclinically or in larger human 
cohorts in vivo. 
As TRIM55 E140K variant potentially increases the susceptibility of heart failure, it 
could be used as a prognostic marker in the clinical genetic screening for heart failure patients. 
Targeting TRIM55 pharmacologically may not be a feasible approach for drug treatment of 
heart failure, as the protein seems to be necessary for normal cardiac function. On the other 
hand, the other members of the pathways TRIM55 is involved in, such as SRF signaling 
pathway, might be viable alternatives as for therapeutic targeting. SRF is a potent inducer of 
hypertrophy [30]. Interestingly, an inhibitor of SRF has been developed for the treatment of 
fibrosis [31]. Testing this molecule in cardiac hypertrophy or heart failure models is an exciting 
avenue for further research. 
A particular limitation of this study is the relatively small number of cases included in 
the genetic association study. We identified signals from a few established heart failure-
associated loci, but without reaching genome-wide-level of significance. However, as our aim 
was to find novel genetic markers and test their functional implications in vitro and in vivo, the 
results are not based solely on GWAS findings. The TRIM55 E140K variant was tested on HL-
1 cardiomyocytes, which provide a robust but not the most sophisticated cardiomyocyte model. 
These cells were selected since they are easy to maintain and they can be passaged multiple 
times, as opposed to primary neonatal cardiomyocytes. Testing the variant in pluripotent human 
stem cell-derived cardiomyocytes would bring the approach to a human cell model, which is an 
important direction for future studies. RNA sequencing experiment was performed on only two 
biological replicates per cell line. However, no batch effects were detected between the 
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replicates, and RT-PCR validation results of the leading edge genes were concordant to RNA 
sequencing results. The in vivo experiments in zebrafish embryo models were performed less 
than five days after fertilization. Therefore, the findings at that time point might be embryo-
specific and the phenotype could be reversed at a later stage of development. Our results 
warrant assessing the implications of the variant in an adult model, preferably mammalian. We 
note, however, that this is the first in-detail assessment of a TRIM55 coding variant in heart 
failure, demonstrating how genetic association studies could be enhanced by functional 
validations in vitro and in vivo. 
In conclusion, the TRIM55 E140K variant was shown to be damaging and potentially 
dominantly negative, and it has functional implications on several cardiomyocyte functions. 
TRIM55 E140K is a potential genetic marker for heart failure prognosis or pathogenesis, which 
warrants further studies to confirm its significance in the human heart. 
 
Acknowledgements 
The authors thank Sanna Timonen, Nora Linnavirta and Daria Bulanova at FIMM and the Core 
facilities Sequencing Unit and Bioinformatics Unit at FIMM Technology Centre supported by 
University of Helsinki and Biocenter Finland for excellent technical and methodological 
assistance. Dr. Antti Hassinen and the High Content Imaging and Analysis (HCA) unit at the 
Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, and 
Biocenter Finland are acknowledged for high content microscopy imaging and image analysis. 
We also thank the bioinformatics (J.V. Lehtonen), translational activities and structural biology 
infrastructure support from Biocenter Finland and Instruct-FI, and CSC IT Center for Science 
for computational infrastructure support at the Structural Bioinformatics Laboratory, Åbo 
Akademi University. The FINRISK data used for the research were obtained from THL 
Biobank. We thank all participants for their generous contribution in the FINRISK study. The 
 24 
flow cytometry analysis was performed at the HiLife Flow Cytometry Unit, University of 
Helsinki and zebrafish experiments at the Zebrafish Core and Cell Imaging Core (both Turku 
Bioscience Centre, University of Turku and Åbo Akademi University). 
 
Funding 
This work has been funded by grants from The Finnish Cultural Foundation (Varsinais-Suomi 
Regional Fund), University of Turku, The Paulo foundation, Inkeri ja Mauri Vänskän säätiö, 
Orion Research Foundation sr, Academy of Finland, Cancer Society of Finland, Sigrid Juselius 
Foundation and Tor, Joe and Pentti Borg’s Foundation. 
 
Disclosures 
JH is employed by and has ownership interest in Abomics Ltd. KE has ownership interest in 
Abomics Ltd., Orion Ltd. and Roche. 
 
References 
[1] A. Mosterd, A.W. Hoes, Clinical epidemiology of heart failure, Heart. 93 (2007) 1137–
1146. https://doi.org/10.1136/hrt.2003.025270. 
[2] G.S. Bleumink, A.M. Knetsch, M.C.J.M. Sturkenboom, S.M.J.M. Straus, A. Hofman, 
J.W. Deckers, et al., Quantifying the heart failure epidemic: Prevalence, incidence rate, 
lifetime risk and prognosis of heart failure - The Rotterdam Study, Eur. Heart J. 25 
(2004) 1614–1619. https://doi.org/10.1016/j.ehj.2004.06.038. 
[3] D.S. Lee, M.J. Pencina, E.J. Benjamin, T.J. Wang, D. Levy, C.J. O’Donnell, et al., 
Association of parental heart failure with risk of heart failure in offspring., N. Engl. J. 
Med. 355 (2006) 138–47. https://doi.org/10.1056/NEJMoa052948. 
[4] U. Tayal, S. Prasad, S.A. Cook, Genetics and genomics of dilated cardiomyopathy and 
 25 
systolic heart failure, Genome Med. 9 (2017) 20. https://doi.org/10.1186/s13073-017-
0410-8. 
[5] T.J. Cahill, H. Ashrafian, H. Watkins, Genetic cardiomyopathies causing heart failure, 
Circ. Res. 113 (2013) 660–675. https://doi.org/10.1161/CIRCRESAHA.113.300282. 
[6] M. Guo, G. Guo, X. Ji, Genetic polymorphisms associated with heart failure: A 
literature review, J. Int. Med. Res. 44 (2016) 15–29. 
https://doi.org/10.1177/0300060515604755. 
[7] S. Perera, M.R. Holt, B.S. Mankoo, M. Gautel, Developmental regulation of MURF 
ubiquitin ligases and autophagy proteins nbr1, p62/SQSTM1 and LC3 during cardiac 
myofibril assembly and turnover, Dev. Biol. 351 (2011) 46–61. 
https://doi.org/10.1016/j.ydbio.2010.12.024. 
[8] M.S. Willis, K.M. Wadosky, J.E. Rodríguez, J.C. Schisler, P. Lockyer, E.G. Hilliard, et 
al., Muscle ring finger 1 and muscle ring finger 2 are necessary but functionally 
redundant during developmental cardiac growth and regulate E2F1-mediated gene 
expression in vivo, Cell Biochem. Funct. 32 (2014) 39–50. 
https://doi.org/10.1002/cbf.2969. 
[9] C.C. Witt, S.H. Witt, S. Lerche, D. Labeit, W. Back, S. Labeit, Cooperative control of 
striated muscle mass and metabolism by MuRF1 and MuRF2, EMBO J. 27 (2008) 
350–360. https://doi.org/10.1038/sj.emboj.7601952. 
[10] M.S. Willis, C. Ike, L. Li, D.Z. Wang, D.J. Glass, C. Patterson, Muscle ring finger 1, 
but not muscle ring finger 2, regulates cardiac hypertrophy in vivo, Circ. Res. 100 
(2007) 456–459. https://doi.org/10.1161/01.RES.0000259559.48597.32. 
[11] J. He, M.T. Quintana, J. Sullivan, T. Parry, T. Grevengoed, J.C. Schisler, et al., MuRF2 
regulates PPARγ1 activity to protect against diabetic cardiomyopathy and enhance 
weight gain induced by a high fat diet, Cardiovasc. Diabetol. 14 (2015) 1–24. 
 26 
https://doi.org/10.1186/s12933-015-0252-x. 
[12] P.R. Prestes, F.Z. Marques, G. Lopez-Campos, S.A. Booth, M. McGlynn, P. 
Lewandowski, et al., Tripartite motif-containing 55 identified as functional candidate 
for spontaneous cardiac hypertrophy in the rat locus cardiac mass 22, J. Hypertens. 34 
(2016) 950–958. https://doi.org/10.1097/HJH.0000000000000875. 
[13] K. Borodulin, E. Vartiainen, M. Peltonen, P. Jousilahti, A. Juolevi, T. Laatikainen, et 
al., Forty-year trends in cardiovascular risk factors in Finland, Eur. J. Public Health. 25 
(2015) 539–546. https://doi.org/10.1093/eurpub/cku174. 
[14] M. Lek, K.J. Karczewski, E. V Minikel, K.E. Samocha, E. Banks, T. Fennell, et al., 
Analysis of protein-coding genetic variation in 60,706 humans, Nature. 536 (2016) 
285–91. https://doi.org/10.1038/nature19057. 
[15] W. McLaren, L. Gil, S.E. Hunt, H.S. Riat, G.R.S. Ritchie, A. Thormann, et al., The 
Ensembl Variant Effect Predictor, Genome Biol. 17 (2016) 122. 
https://doi.org/10.1186/s13059-016-0974-4. 
[16] M. Su, J. Wang, L. Kang, Y. Wang, Y. Zou, X. Feng, et al., Rare variants in genes 
encoding MuRF1 and MuRF2 are modifiers of hypertrophic cardiomyopathy, Int. J. 
Mol. Sci. 15 (2014) 9302–9313. https://doi.org/10.3390/ijms15069302. 
[17] M. Mrosek, S. Meier, Z. Ucurum-Fotiadis, E. von Castelmur, E. Hedbom, A. Lustig, et 
al., Structural analysis of B-Box 2 from MuRF1: Identification of a novel self-
association pattern in a RING-like fold, Biochemistry. 47 (2008) 10722–10730. 
https://doi.org/10.1021/bi800733z. 
[18] P.S. Brzovic, P. Rajagopal, D.W. Hoyt, M. King, R.E. Klevit, Structure of a BRCA1 – 
BARD1 heterodimeric RING – RING, Nat. Struct. Biol. 8 (2001) 833–7. 
[19] W. Song, H. Wang, Q. Wu, Atrial natriuretic peptide in cardiovascular biology and 
disease (NPPA), Gene. 569 (2015) 1–6. https://doi.org/10.1016/j.gene.2015.06.029. 
 27 
[20] S. Lange, F. Xiang, A. Yakovenko, A. Vihola, P. Hackman, E. Rostkova, et al., The 
kinase domain of titin controls muscle gene expression and protein turnover, Science 
(80-. ). 308 (2005) 1599–1603. https://doi.org/10.1126/science.1110463. 
[21] V. Pizon, S. Rybina, F. Gerbal, F. Delort, P. Vicart, G. Baldacci, et al., MURF2B, a 
Novel LC3-Binding Protein, Participates with MURF2A in the Switch between 
Autophagy and Ubiquitin Proteasome System during Differentiation of C2C12 Muscle 
Cells, PLoS One. 8 (2013) 1–21. https://doi.org/10.1371/journal.pone.0076140. 
[22] S.H. Witt, H. Granzier, C.C. Witt, S. Labeit, MURF-1 and MURF-2 Target a Specific 
Subset of Myofibrillar Proteins Redundantly: Towards Understanding MURF-
dependent Muscle Ubiquitination, J. Mol. Biol. 350 (2005) 713–722. 
https://doi.org/10.1016/j.jmb.2005.05.021. 
[23] J.Y. Kim, K.S. Tillison, S. Zhou, J.H. Lee, C.M. Smas, Differentiation-Dependent 
Expression of Adhfe1 in Adipogenesis, Arch Biochem Biophys. 464 (2007) 100–111. 
[24] P. Mishra, W. Tang, S. Ambs, ADHFE1 is a MYC-linked oncogene that induces 
metabolic reprogramming and cellular de-differentiation in breast cancer, Mol. Cell. 
Oncol. 5 (2018) e1432260. https://doi.org/10.1080/23723556.2018.1432260. 
[25] D. Shiffman, S. Trompet, J.Z. Louie, C.M. Rowland, J.J. Catanese, O.A. Iakoubova, et 
al., Genome-wide study of gene variants associated with differential cardiovascular 
event reduction by pravastatin therapy, PLoS One. 7 (2012) e38240. 
https://doi.org/10.1371/journal.pone.0038240. 
[26] Exome Aggregation Consortium. ExAC Browser., (2019). 
http://exac.broadinstitute.org (accessed June 4, 2019). 
[27] F.J. Davis, M. Gupta, S.M. Pogwizd, E. Bacha, V. Jeevanandam, M.P. Gupta, 
Increased expression of alternatively spliced dominant-negative isoform of SRF in 
human failing hearts, Am. J. Physiol. - Hear. Circ. Physiol. 282 (2002) H1521-1533. 
 28 
https://doi.org/10.1152/ajpheart.00844.2001. 
[28] A. Parlakian, C. Charvet, B. Escoubet, M. Mericskay, J.D. Molkentin, G. Gary-Bobo, 
et al., Temporally controlled onset of dilated cardiomyopathy through disruption of the 
SRF gene in adult heart, Circulation. 112 (2005) 2930–2939. 
https://doi.org/10.1161/CIRCULATIONAHA.105.533778. 
[29] Y. Guo, B.D. Jardin, P. Zhou, I. Sethi, B.N. Akerberg, C.N. Toepfer, et al., 
Hierarchical and stage-specific regulation of murine cardiomyocyte maturation by 
serum response factor, Nat. Commun. (2018). https://doi.org/10.1038/s41467-018-
06347-2. 
[30] N. Frey, E.N. Olson, Cardiac Hypertrophy: The Good, the Bad, and the Ugly, Annu. 
Rev. Physiol. 65 (2003) 45–79. 
https://doi.org/10.1146/annurev.physiol.65.092101.142243. 
[31] C. Yu-Wai-Man, B. Spencer-Dene, R.M.H. Lee, K. Hutchings, E.M. Lisabeth, R. 
Treisman, et al., Local delivery of novel MRTF/SRF inhibitors prevents scar tissue 





Figure 1. Missense E140K variant in TRIM55 is in high LD with a variant highly associated 
with heart failure. 
A) A LocusZoom plot of rs117667921 in chromosome 8 associated with heart failure. The 
exonic variant rs138811034, encoding E140K protein variant, in TRIM55 (highlighted in red 
square) was found out to be in high LD (D’ = 1) with the lead variant rs117667921. 
Rs138811034 is not depicted in the figure since its independent association with heart failure 
was not statistically significant (P = 0.377) and its P-value was below the threshold for the 
variants shown here. B) The effect on E140K variation on the surface charge of TRIM55 B2. 
E140 is located on the dimer 2 interface and contributes to the negatively charged surface area 
in the wild-type protein. One of the monomers of dimer 2 is shown as surface and the other one 
as orange cartoon. The zinc ions are shown as spheres. C) K140 in the E140K variant switches 
the surface area positively charged, which plausibly has a harmful effect on the formation of 
higher-order oligomers and heterodimeric interactions. 
 
Figure 2. Characterization of HL-1 cardiomyocyte-derived cell lines carrying Trim55 variants. 
A) Sequencing chromatograms of Trim55 of the cell lines used in validations. Underlined part 
in the sequence of WT/WT cell line depicts the binding site of the antisense sgRNA used in 
generating the mutant lines (PAM motif underlined in red). In E140K/- line, the E140K-coding 
variant (c.418G>A) is shown boxed and marked with an asterisk. Additionally, three silent 
mutations included in the HDR template to prevent further binding of sgRNA after editing are 
shown boxed in the same allele. Corresponding wildtype sequences after short deletions in 
deletion alleles are shown boxed. Corresponding protein sequences, with amino acids differing 
from wildtype marked in red, are shown under the sequences. B) A representative Western blot 
image and quantitation of TRIM55 protein expression from four independent samples of 
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Trim55 variant cell lines. Molecular weight scales next to Western blot images are in 
kilodaltons. C) Trim55 mRNA expression analysis with quantitative RT-PCR from three 
independent samples of Trim55 variant cell lines.  
 
Figure 3. Genes related to cardiac contractility and stress are regulated in Trim55 E140K/- 
cells. 
A) Unsupervised hierarchical clustering of Trim55 variant cell lines according to 82 most highly 
regulated genes in all variant cell lines. WT/- cells form a distinct cluster while E140K/- and -
/- cells cluster together. B) The most significantly regulated GO term gene sets in E140K/- cells 
as compared to WT/WT cells in GSEA analysis. NES, normalized enrichment score. C) 
Heatmap representation of unsupervised hierarchical clustering of Trim55 variant cell lines 
according to top-10 leading edge genes of 
GO_REGULATION_OF_MUSCLE_CONTRACTION pathway. E140K/- and -/- cells cluster 
together as opposed to the cluster of WT/WT and WT/- cells. D) Quantitative RT-PCR 
validation of the three leading edge genes in the pathway from three independent validation 
samples. In E140K/- cells, the expression of Nppa, Myl7 and Adra2b mRNA (normalized to 
B2m expression) was in concordance with RNA-seq results as compared to WT/WT cells. Bars 
represent means and error bars SEMs (n = 3 for RT-PCR experiments and n = 2 for RNA-seq). 
Results for each gene were normalized to control gene B2m and the expression level of WT/WT 
was set to one. 
 
Figure 4. Trim55 E140K/- cells demonstrate reduced viability and decreased cell cycle 
progression and are prone to hypertrophy. 
A) Cellular viability measured with CTG assay from Trim55 variant cell lines grown on 96-
well plate wells (n = 3 for all cell lines). B) A representative Western blot image and 
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quantitation of p21 protein expression from five independent samples of Trim55 variant cell 
lines. C) Flow cytometry-based cell cycle analysis of Trim55 variant cell lines after PI staining 
(n = 4 for all cell lines). Molecular weight scales next to Western blot images are in kilodaltons. 
D) Representative immunofluorescence images of Trim55 variant cell lines treated with or 
without 100 μM of isoproterenol (ISO) for 48 hours to induce hypertrophy. Cells were stained 
with anti-myosin heavy chain antibody (green) to visualize cell surface area and nuclei were 
visualized with Hoechst (blue). Scale bar, 50 μm. E) Boxplot presentation of quantitated cell 
surfaces from Trim55 variant cell lines from isoproterenol experiment. Cell surfaces were 
manually traced from immunofluorescence images. Due to variation in average cell sizes in 
different cell lines, medians of untreated controls of all cell lines are normalized to unity for 
visualization purposes (282-484 cells per each group were analyzed). 
 
Figure 5. CRISPR-mediated knockout of trim55a or overexpression of human TRIM55 E140K 
reduce cardiac contractility in zebrafish embryos.  
A) A representative sequencing chromatogram from a trim55a-edited zebrafish embryo 
around the sgRNA binding sites in exon 2. The binding site of trim55a sgRNAs are shown 
underlined (PAM motif underlined with red). The double peaks are caused by disruption of 
the genome. B) Boxplot presentations of fractional shortening and heart rate (beats per 
minute) measured at four days post fertilization from uninjected embryos (n = 16) and 
embryos injected at 1-4-cell stage with control sgRNAs (n = 24) or trim55a-targeting sgRNAs 
(n = 23). C) Representative brightfield and fluorescence images of a GFP control plasmid-
injected embryo demonstrating heart- specific expression of the construct (boxed). Scale bar, 
500 μm. D) Boxplot presentations of fractional shortening and heart rate (beats per minute) 
measured at four days post fertilization from uninjected embryos (n = 18) and embryos 
injected at 1-4-cell stage with GFP-control plasmid (n = 27), human TRIM55 WT plasmid (n 
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Pathway Adj. P -value NES Pathway size
GO_REGULATION_OF_MUSCLE_CONTRACTION 0.021 1.510 142
GO_MUSCLE_SYSTEM_PROCESS 0.021 1.479 259
GO_REGULATION_OF_MUSCLE_SYSTEM_PROCESS 0.021 1.458 194
GO_EXTRACELLULAR_STRUCTURE_ORGANIZATION 0.021 1.444 192
GO_MUSCLE_CONTRACTION 0.021 1.442 211
GO_CONTRACTILE_FIBER 0.021 1.428 219
GO_REGULATION_OF_HEART_CONTRACTION 0.021 1.418 202
GO_GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY 0.021 1.413 265
GO_MUSCLE_TISSUE_DEVELOPMENT 0.021 1.398 288
GO_CALCIUM_ION_BINDING 0.021 1.389 363
GO_CIRCULATORY_SYSTEM_PROCESS 0.021 1.386 294
GO_REGULATION_OF_SYSTEM_PROCESS 0.021 1.386 385
GO_WOUND_HEALING 0.021 1.353 368
GO_RESPONSE_TO_WOUNDING 0.021 1.344 440
GO_PURINE_CONTAINING_COMPOUND_METABOLIC_PROCESS 0.021 1.336 319
GO_ACTIN_CYTOSKELETON 0.021 1.335 436
GO_MUSCLE_STRUCTURE_DEVELOPMENT 0.021 1.322 425
GO_SKELETAL_SYSTEM_DEVELOPMENT 0.021 1.318 363
GO_HEART_DEVELOPMENT 0.021 1.307 490
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